Patents by Inventor Klaus T. Preissner

Klaus T. Preissner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7998932
    Abstract: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis mediated by alpha-defensins.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: August 16, 2011
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Douglas Cines, Khalil Bdeir, Klaus T. Preissner, Triantafylios Chavakis
  • Patent number: 7576060
    Abstract: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis.mediated by alpha-defensins.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: August 18, 2009
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Douglas Cines, Khalil Bdeir, Triantafyllos Chavakis, Klaus T. Preissner
  • Publication number: 20090075893
    Abstract: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis mediated by alpha-defensins.
    Type: Application
    Filed: October 8, 2008
    Publication date: March 19, 2009
    Inventors: Douglas Cines, Khalil Bdeir, Klaus T. Preissner, Triantafylios Chavakis
  • Publication number: 20080234189
    Abstract: A method of treatment of a mammal suffering from an inflammatory condition or a cancer includes administering an anti-inflammatory protein or a peptide fraction of the protein having at least one repeating unit, the protein being selected from a group of proteins designated Eap (Extracellular adherence protein). The inflammatory condition may be a non-bacterial or bacterial inflammation.
    Type: Application
    Filed: October 1, 2007
    Publication date: September 25, 2008
    Inventors: Jan-Ingmar FLOCK, Triantafyllos Chavakis, Mathias Herrmann, Klaus T. Preissner
  • Publication number: 20030105020
    Abstract: A method of treatment of a mammal suffering from an inflammatory condition by administration of an anti-inflammatory drug comprising a protein or a peptide fraction of said protein comprising at least one repeating unit thereof, said protein being selected from a group of proteins designated Eap (Extracellular adherence protein). The inflammatory condition may be a non-bacterial or bacterial inflammation.
    Type: Application
    Filed: November 18, 2002
    Publication date: June 5, 2003
    Inventors: Jan-Ingmar Flock, Triantafyllos Chavakis, Mathias Herrmann, Klaus T. Preissner
  • Publication number: 20030077271
    Abstract: The use of coagulation factor VII-activating protease (FSAP) for the prophylaxis and/or therapy of vasoproliferative disorders or oncoses is described. Reference is made in particular to the use of the protease for retinopathy, neuropathy, rheumatoid arthritis, psoriasis, endometriosis, bronchitis (especially chronic) or chronic inflammations in the gastrointestinal tract.
    Type: Application
    Filed: September 26, 2002
    Publication date: April 24, 2003
    Inventors: Christian Kannemeier, Juergen Roemisch, Klaus T. Preissner, Sandip Kanse